Fig. 1.

Serum osteolectin levels in premenopausal women with idiopathic osteoporosis after receiving PTH treatment. Osteolectin levels were measured in blinded patient samples at baseline and then at 3, 6, and 12 mo after initiating Teriparatide treatment. The levels are shown as a percentage of the level in the same patient at baseline. (A) Serum osteolectin levels in all patients (n = 40). (B) Serum osteolectin levels in responders (n = 32) and nonresponders (n = 8) to Teriparatide. These groups were prespecified based on a prior study (47). (C) Correlation between the percentage change in lumbar spine bone mineral density and the percentage change in serum osteolectin levels in all patients after 12 mo of Teriparatide treatment (n = 34). All data represent mean ± SD. Statistical significance was assessed using two-sided, one-sample Wilcoxon signed rank tests for time points compared to baseline followed by multiple comparisons adjustment using the Holm–Sidak method (A), two-way ANOVAs followed by the Holm–Sidak method (B), or a simple linear regression with the Spearman correlation test (C); *P < 0.05, **P < 0.01, ***P < 0.001.